Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D'Amico Intermediate-/High-Risk Prostate Cancer in Older Patients.
3D conformal external beam radiotherapy
androgen deprivation therapy
localized prostate cancer
older adults
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Dec 2020
29 Dec 2020
Historique:
received:
19
11
2020
revised:
18
12
2020
accepted:
24
12
2020
entrez:
1
1
2021
pubmed:
2
1
2021
medline:
2
1
2021
Statut:
epublish
Résumé
The association of 3D Conformal External Beam Radiotherapy (3D-CEBRT) with adjuvant Androgen Deprivation Therapy (ADT) proved to treat patients with intermediate- and high-risk localized prostate cancer (IR and HR). However, older patients were underrepresented in literature. We aimed to report the oncological results and morbidity 3D-CEBRT +ADT in ≥80 years patients. From June 1998 to July 2017, 101 patients ≥80 years were included in a tertiary center. The median age was 82 years. ADT was initiated 3 months prior 3D-CEBRT in all patients, with a total duration of 6 months for IR prostate cancer (group A; Five years-OS was 95% and 86.7% in groups A and B, respectively. Cardiovascular events occurred in 22.8% of ≥80 years patients with no impact on OS. In the multivariate analysis, age <82 years, Karnofsky index and normalization of testosterone levels were significantly associated with better OS. Age ≥80 years should not be a limitation for the treatment of IR and HR prostate cancer patients with 3D-CEBRT and ADT, but cardiovascular monitoring and prevention are mandatory.
Identifiants
pubmed: 33383957
pii: cancers13010075
doi: 10.3390/cancers13010075
pmc: PMC7795189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2011 Dec 7;306(21):2359-66
pubmed: 22147380
Radiother Oncol. 2011 Dec;101(3):460-4
pubmed: 21864924
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Geriatr Med. 2009 Nov;25(4):563-77, vii
pubmed: 19944261
Eur J Cancer. 2019 Jul;116:116-136
pubmed: 31195356
J Clin Endocrinol Metab. 2002 Feb;87(2):589-98
pubmed: 11836290
Lancet. 2009 Jan 24;373(9660):301-8
pubmed: 19091394
BMC Cancer. 2015 Nov 02;15:837
pubmed: 26525985
J Clin Oncol. 2008 Feb 1;26(4):585-91
pubmed: 18172188
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
N Engl J Med. 2005 Jan 13;352(2):154-64
pubmed: 15647578
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90
pubmed: 15817329
Cancer. 1998 Jan 15;82(2):334-41
pubmed: 9445191
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):191-9
pubmed: 21109361
Urology. 2004 Apr;63(4):742-5
pubmed: 15072892
Cancer. 2003 Jan 1;97(1):56-62
pubmed: 12491505
Lancet. 2011 Dec 17;378(9809):2104-11
pubmed: 22056152
J Clin Oncol. 1998 Apr;16(4):1582-7
pubmed: 9552069
Lancet Oncol. 2011 May;12(5):451-9
pubmed: 21440505
J Clin Oncol. 2016 May 20;34(15):1748-56
pubmed: 26976418
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Eur Urol. 2015 Sep;68(3):386-96
pubmed: 25484142
PLoS One. 2018 Apr 9;13(4):e0194173
pubmed: 29630602
Cancer. 2007 Dec 15;110(12):2604-13
pubmed: 17960609
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Lancet Oncol. 2012 Jun;13(6):e259-69
pubmed: 22652234
Lancet Oncol. 2014 Aug;15(9):e404-14
pubmed: 25079103
Lancet. 2017 Apr 1;389(10076):1323-1335
pubmed: 28236464
JAMA. 2008 Jan 23;299(3):289-95
pubmed: 18212313
J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19
pubmed: 21816776
Support Care Cancer. 2013 Jun;21(6):1761-71
pubmed: 23455492
Prog Urol. 2005 Apr;15(2):260-4
pubmed: 15999604
J Clin Oncol. 2011 Jan 10;29(2):235-41
pubmed: 21135285
J Urol. 2006 Dec;176(6 Pt 1):2443-7
pubmed: 17085125
PLoS One. 2014 Sep 29;9(9):e107516
pubmed: 25264674
Cancer. 2004 Jan 1;100(1):72-81
pubmed: 14692026
J Clin Oncol. 2003 May 1;21(9):1653-9
pubmed: 12721238